Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study

Lei Lei Wu

News Reporter

Biohaven is seeking to reverse the fate of its embattled experimental drug troriluzole in spinocerebellar ataxia — a degenerative muscle disease — using new clinical trial results …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

UCB adds three more FDA approvals to label for potential blockbuster Bimzelx

Telix buys radiopharmacy network for $230M up front to expand US capacity

Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Over a year af­ter FDA re­jec­tion, Bio­haven claims suc­cess in piv­otal mus­cle dis­ease study

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Q&A: Bris­tol My­ers’ tech chief on the promis­es and per­ils of AI bio

As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

UCB adds three more FDA ap­provals to la­bel for po­ten­tial block­buster Bimzelx

Telix buys ra­dio­phar­ma­cy net­work for $230M up front to ex­pand US ca­pac­i­ty

Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

UCB adds three more FDA approvals to label for potential blockbuster Bimzelx

Telix buys radiopharmacy network for $230M up front to expand US capacity

Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships